Citius pharmaceuticals reports strong clinical community engagement during mino-lok® phase 3 trial-related webinar

Cranford, n.j., april 29, 2021 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced updates delivered during its third mino-lok® phase 3 trial-related webinar.
CTXR Ratings Summary
CTXR Quant Ranking